Listen to the article
A judge signaled Friday his intention to approve a landmark settlement between OxyContin maker Purdue Pharma, members of the Sackler family, and thousands of plaintiffs over the company’s role in the U.S. opioid crisis. U.S. Bankruptcy Court Judge Sean Lane indicated he would provide detailed reasoning for his decision next week.
The settlement marks a pivotal moment in the legal battle against key players in America’s devastating opioid epidemic, which has claimed approximately 900,000 lives in the United States since 1999, including deaths from heroin and illicit fentanyl.
Under the terms of the agreement, members of the Sackler family will contribute up to $7 billion and relinquish ownership of Purdue Pharma, a company that has been under their control for decades. Financial records reveal that family members received more than $10 billion from the company in the decade before departing from its board of directors in 2018, with approximately half that amount going toward taxes.
The settlement imposes significant restrictions on the Sacklers, prohibiting them from participating in the opioid business internationally and barring them from having their names displayed on institutions through charitable contributions. This provision formalizes a trend already in motion, as numerous museums and universities have previously severed ties with the family due to their controversial legacy.
Purdue Pharma, headquartered in Stamford, Connecticut, will undergo a complete transformation as part of the deal. The company will be renamed Knoa Pharma and restructured as a public benefit entity with a board appointed by state officials. While it may continue producing OxyContin, the restructured company’s profits will be directed toward addressing the nation’s opioid crisis.
The settlement includes provisions for independent monitoring of the company, continuing oversight that has been in place for several years. Purdue has also agreed to make millions of internal documents public, including those typically protected by attorney-client privilege, increasing transparency about its business practices.
The company still faces formal sentencing related to its 2020 guilty plea with the U.S. Department of Justice, wherein it admitted to paying doctors through a speakers program to increase prescriptions and maintaining inadequate safeguards against diversion to the black market.
A distinctive feature of the Purdue settlement compared to other opioid settlements—which collectively total approximately $50 billion—is its provision for individual victim compensation. Approximately $850 million has been allocated for victims, with more than $100 million specifically designated for the care of children born suffering from withdrawal symptoms.
While government entities may receive their portions over a 15-year period, individual victims are expected to receive payments as early as next spring. However, the compensation amounts have been a source of frustration for many victims. Those who qualify by demonstrating they were prescribed OxyContin are anticipated to receive only about $8,000 or $16,000 each, depending on their duration of use.
The road to this settlement has been complex. A previous settlement plan approved in 2021 was overturned by the U.S. Supreme Court, which ruled that Sackler family members would have improperly received protection from lawsuits despite not filing for bankruptcy protection themselves.
The revised settlement addresses this issue by allowing entities that don’t participate in the deal to pursue lawsuits against Sackler family members over opioid-related claims. The city of Baltimore has already indicated it may pursue such litigation.
The current settlement appears more likely to withstand legal challenges, as no parties represented by legal counsel objected to the plan by the conclusion of this week’s hearing. Only a small number of individual victims without legal representation continued to voice opposition.
As the settlement moves forward, it represents a significant step in addressing accountability for one of America’s most devastating public health crises, though many argue the financial penalties and restructuring requirements still fall short of true justice for the epidemic’s victims.
Fact Checker
Verify the accuracy of this article using The Disinformation Commission analysis and real-time sources.
9 Comments
This settlement is a significant step in holding Purdue Pharma and the Sackler family accountable for their role in the opioid crisis. While the monetary damages may provide some compensation for victims, the true impact will be in the relinquishment of control and the restrictions placed on the Sacklers going forward.
Agreed. Removing the Sackler name from institutions is an important symbolic gesture, though the true justice will come in the reforms and changes to prevent such tragedies from happening again.
While the financial penalties and relinquishment of control are meaningful, the true test of this settlement will be whether it leads to substantive changes in the pharmaceutical industry and the prevention of similar public health crises in the future. The opioid epidemic has been devastating, and accountability is essential.
Well said. The human cost of the opioid crisis is immeasurable, and this settlement, while an important step, must be followed by sustained efforts to reform the industry and address the underlying systemic issues that allowed this tragedy to unfold.
It’s good to see the legal system holding Purdue Pharma and the Sackler family accountable, but the real challenge will be ensuring that the changes enacted as a result of this settlement lead to meaningful reform and prevent similar public health disasters in the future. The opioid crisis has been devastating, and true justice will come in the form of lasting, systemic change.
The scale of the opioid crisis in the US is truly staggering, with nearly 900,000 lives lost. This settlement, while not a complete solution, is an important step towards accountability and providing some measure of justice for the victims and their families.
I agree that the magnitude of the crisis underscores the importance of this settlement, even if it doesn’t fully resolve the issue. The restrictions placed on the Sacklers are a significant development, but the real test will be the long-term impact on public health and the prevention of future opioid epidemics.
It’s encouraging to see the legal system working to hold powerful entities responsible for their actions, even if the process has been long and arduous. This settlement, while not a complete resolution, does represent progress in addressing the devastating opioid crisis.
You raise a fair point. While the financial penalties are substantial, the true test will be whether the systemic changes enacted as part of this settlement lead to meaningful reform and prevent similar tragedies in the future.